Navigation Links
Experts call for further research into the relationship between insulin therapy and cancer
Date:3/2/2010

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.

Cancer expert Professor Michael Pollak from McGill University, Montreal, Canada, teamed up with diabetes expert Professor David Russell-Jones from The Royal Surrey County Hospital, Guildford, UK, to review more than three decades of laboratory and population studies.

They believe that their findings will be of special interest to clinicians advising diabetic patients who have also been diagnosed with cancer or have a strong family history of cancer.

"The inter-relationships between cancer and diabetes deserve more attention as both of these diseases are becoming more prevalent globally and it is increasingly more common to see patients with both conditions" says Professor Pollak.

The paper also reflects the views expressed by experts at scientific meetings held in 2009 to assess the relative risk of malignancy associated with diabetes itself and with the use of different insulin products and other diabetes treatments. These meetings followed the publication of a series of epidemiological studies in 2009 that raised questions concerning the relative risk of cancer incidence associated with the basal insulin analogue, insulin glargine.

"Recent publications have resurrected awareness and focused attention on an issue that first emerged more than a decade ago, when it was shown that artificial modification of the molecular structure of insulin could result in increased cell division" says Professor Pollak.

"Our review showed that people with diabetes, particularly those with type 2 diabetes, may face an increased risk of cancer and that their cancer may be modified by treatment choices.

"Research suggests that metformin, which is used to treat some patients with diabetes, may provide a protective effect, while insulin and/or certain insulin analogues may promote tumour growth."

The review found that diabetes appears to be associated with an intrinsic increase in cancer incidence. A number of meta-analyses have been carried out, showing that:

  • Diabetic patients were 30 per cent more likely to develop colorectal cancer (15 studies covering 2.5 million patients).

  • Women with diabetes had a 20 per cent greater risk of developing breast cancer, according to 20 studies.

  • People with diabetes had an 82 per cent higher risk of developing pancreatic cancer (36 studies covering more than 9,000 patients).

"The excess risk of pancreatic cancer was highest among those who had only had diabetes a short time, suggesting that the cancer could cause the diabetes" says Professor Pollak. "However, the incidence of this cancer in people with a longer history of diabetes does suggest there may also be an intrinsic cancer risk from diabetes.

"It is also important to remember that diabetes is often associated with other illnesses and risk factors, such as obesity and physical inactivity, that may in themselves increase the cancer risk."

The authors are keen to point out that the current evidence is far from clear-cut and further research is needed to examine the risks and mechanisms that appear to link insulin with tumour growth.

"In the meantime, we agree with statements issued by the major diabetes organisations that there is no need to panic" says Professor Pollak. "Insulin has an excellent risk benefit ratio and any absolute risks between the different treatments are likely to be small.

"However, careful consideration of the choices available might be wise for patients who face a high biological risk of cancer, for example those with a family or personal history of cancer. Clinicians need to be prepared to provide up-to-date advice to these people, as ongoing research continues.

"It is important to recognise that the initially surprising observation that diabetics receiving metformin treatment are substantially less likely to have cancer than expected have now been reproduced in several studies. The possibility that this off-patent drug may have uses in cancer prevention or treatment, as well as in the treatment of type 2 diabetes, is receiving serious attention from research teams of endocrinologists and oncologists."

The authors believe that future work may uncover links between insulin use and cancer risk. "Laboratory experiments have shown that some cancers respond to insulin and there are precedents where hormone therapy increases cancer risk, such as post-menopausal oestrogen replacement" says Professor Pollak.

"However, the absolute risks involved need to be characterised and placed in the context of the high absolute risks for the other more familiar morbid endpoints of diabetes. We must not lose sight of the fact that the most pressing issues facing the majority of people with diabetes, and their physicians, are those relating to glucose control and the reduction of the well-known and serious consequences of poorly controlled diabetes."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. FDA Appoints Highly Qualified Scientific Experts to Tobacco Products Scientific Advisory Committee
2. Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3
3. Experts call for acceleration of research and interventions for prematurity and stillbirth
4. Local Carrollton Center Hosting More than 50 Autism Experts from Coast-to-Coast
5. Labor and Employee Relations Experts Form New Consulting Firm
6. Canada's Top Health, Nutrition and Lifestyle Experts Come Together On Brand-New Website
7. Informatics experts contribute to special Health Affairs edition on e-health in the developing world
8. As Swine Flu Fades, Experts Ponder Next Season
9. Peer Review Experts Have Weighed In ... WEIGHLEVEL Is a Proven Winner
10. Chiropractors at Lyn Lake Chiropractic Clinic Provide Minneapolis, MN, Resource As Official MyFoxTwinCities.com ASK THE EXPERTS Sponsor
11. Experts Issue Warning on Prostate Hormone Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: